Effect of the Antioxidants Selenium and Beta-carotene on HIV-related Endothelium Dysfunction

Summary

Patients infected with HIV are at increased risk of atherosclerosis, and have evidence of endothelium dysfunction. The hypothesis was tested that HIV-related endothelium dysfunction is related to loss of antioxidants. This was done by the supplementation of the antioxidants selenium and beta-carotene. We supplemented the diet of 10 HIV-sero-positive subjects with 100 μg selenium daily, 11 subjects with 30 mg beta-carotene twice daily while 15 subjects were not supplemented. Plasma was obtained at outset and after a year, and tested by ELISA for endothelial cell, platelet and inflammatory markers.

The non-supplemented patients experienced increases in von Wille-brand factor and soluble thrombomodulin (both p < 0.01). There were no changes in any of the indices in the patients taking selenium or beta-carotene.

Increased von Willebrand factor and soluble thrombomodulin in the non-supplemented patients imply increased damage to the endothelium over the year of the study. Therefore we interpret the lack of increase in the patients taking antioxidants as evidence of the protection of the endothelium by these agents.

• References

• 1 Constans J, Seigneur M, Blann AD, Conri Cl. Is there a link between Human Immunodeficiency Virus and atherosclerosis-related diseases?. Lancet 1997; 350: 1030.
• 2 Tabib A, Greenland T, Mercier I, Loire R, Mornex JF. Coronary lesions in young HIV-positive patients. Lancet 1992; 340: 730.
• 3 Capron L, Kim YU, Laurin C, Bruneval P, Fiessinger JN. Atheroembolism in HIV-positive individuals. Lancet 1992; 340: 1039-40.
• 4 Constans J, Marchand JM, Conri C. et al. Asymptomatic atherosclerosis in HIV-positive patients: a case-controlled ultrasound study. Ann Med 1995; 27: 683-5.
• 5 Constans J, Pellegrin JL, Peuchant E, Dumon MF, Pellegrin I, Sergeant C, Simonoff M, Brossard G, Barbeau P, Fleury H, Clerc M, Leng B, Conri C. Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest 1994; 24: 416-20.
• 6 Constans J, Peuchant E, Pellegrin JL. et al. Fatty acids and plasma antoxidants in HIV-positive patients: correlation with nutritional and immunological status. Clin Biochem 1995; 28: 421-6.
• 7 Lafeuillade A, Alessi MC, Poizot-Martin I, Boyer Neumann C, Zandotti C, Quilichini R, Aubert L, Tamalet C, Juhan-Vague I, Gastaut JA. Endothelial cell dysfunction in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1992; 5: 127-31.
• 8 Seigneur M, Constans J, Blann AD, Renard M, Pellegrin JL, Amiral J, Boisseau MR, Conri C. Soluble adhesion molecules and endothelial cell damage in HIV infected patients. Thromb Haemost 1997; 77: 646-9.
• 9 Blann AD, Seigneur M, Constans J, Pellegrin JL, Conri Cl.. Soluble p-selectin, thrombocytopenia and von Willebrand factor in HIV infected patients. Thromb Haemost 1997; 77: 1215-24.
• 10 Constans J, Delmas-Beauvieux MC, Sergeant C, Peuchant E, Pellegrin JL, Pellegrin I, Clerc M, Fleury H, Simonoff M, Leng B, Conri C. One-year antioxidant supplementation with β-carotene or selenium for patients infected with Human Immunodeficiency Virus: a pilot study. Clin Infect Dis 1996; 23: 654-6.
• 11 Delmas-Beauvieux MC, Peuchant E, Couchouron A, Constans J, Sergeant C, Simonoff M, Pellegrin JL, Leng B, Conri C, Clerc M. The enzymatic antioxidant system in blood and glutathione status in Human Immuno-deficiency Virus-1 (HIV)-infected patients: effects of supplementation with selenium or β-carotene. Am J Clin Nutr 1996; 64: 101-7.
• 12 Seigneur M, Dufourcq P, Conri C, Constans J, Mercié P, Pruvost A, Boisseau MR. Plasma thrombomodulin: new approach of endothelium damage. Int Angiol 1993; 12: 355-9.
• 13 Blann AD, Mc Collum CN. Circulating endothelial cell/leukocyte adhesion molecules in atherosclerosis. Thromb Haemost 1994; 72: 151-4.
• 14 Blann AD, Lipp GYH. Hypothesis: is soluble P-selectin a new marker for platelet activation?. Atherosclerosis 1997; 128: 135-8.
• 15 Blann AD, Taberner DA. A reliable marker of endothelial cell damage. Does it exist? Br J Haematol 1995; 90: 244-8.
• 16 Fijnheer R, Frijns CJM, Korteweg J, Rommes H, Peters JH, Sixma JJ, Nieuwenhuis HK. The origin of P-selectin as circulating plasma protein. Thromb Haemostas 1997; 77: 1081-85.
• 17 Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-9.
• 18 Constans J, Pellegrin JL, Sergeant C, Simonoff M, Pellegrin I, Fleury H, Leng B, Conri C. Serum selenium predicts outcome in HIV infection. J Acquir Immune Defic Syndr Retrovirol 1995; 10: 392.
• 19 Roederer M, Staal FJT, Anderson MT, Herznberg LA. Glutathione deficiency and Human Immunodeficiency Virus infection. Lancet 1992; 339: 909-12.
• 20 Ishii H, Uchiyama H, Kazama M. Soluble thrombomodulin antigen in conditioned medium is increased by damage to endothelial cells. Thromb Haemost 1991; 65: 618-23.
• 21 Pigott R, Dilon P, Hemingway IH, Gearing AJH. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Comm 1921; 87: 584-9.
• 22 Stephens N, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ, Brown MJ. Randomised control trial of vitamin E in patients with coronary disease. Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347: 781-6.
• 23 Diaz MN, Frei B, Vita JA, Keaney JF. Antioxidants and atherosclerotic heart disease. N Eng J Med 1997; 337: 408-16.